Hasegawa Y - Search Results

1

Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

Ando Y, Tateishi T, Sekido Y, Yamamoto T, Satoh T, Hasegawa Y, Kobayashi S, Katsumata Y, Shimokata K, Saito H. Ando Y, et al. Among authors: hasegawa y. J Natl Cancer Inst. 1999 Sep 15;91(18):1587-90. doi: 10.1093/jnci/91.18.1587. J Natl Cancer Inst. 1999. PMID: 10491442 No abstract available.

2

Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.

Ando M, Ando Y, Sekido Y, Ando M, Shimokata K, Hasegawa Y. Ando M, et al. Among authors: hasegawa y. Jpn J Cancer Res. 2002 May;93(5):591-7. doi: 10.1111/j.1349-7006.2002.tb01295.x. Jpn J Cancer Res. 2002. PMID: 12036456 Free PMC article.

3

Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia.

Ando M, Ando Y, Hasegawa Y, Sekido Y, Shimokata K, Horibe K. Ando M, et al. Among authors: hasegawa y. Pharmacogenetics. 2001 Apr;11(3):269-73. doi: 10.1097/00008571-200104000-00011. Pharmacogenetics. 2001. PMID: 11337943 No abstract available.

4

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Ando Y, et al. Among authors: hasegawa y. Cancer Res. 2000 Dec 15;60(24):6921-6. Cancer Res. 2000. PMID: 11156391

5

Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.

Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S. Ando M, et al. Among authors: hasegawa y. Br J Cancer. 2001 Nov 30;85(11):1634-9. doi: 10.1054/bjoc.2001.2162. Br J Cancer. 2001. PMID: 11742480 Free PMC article.

6

[Future directions of gene therapy for lung cancer].

Hasegawa Y, Shimokata K. Hasegawa Y, et al. Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Dec;33 Suppl:33-7. Nihon Kyobu Shikkan Gakkai Zasshi. 1995. PMID: 8752480 Review. Japanese.

7

Prediction equation for glomerular filtration rate.

Ando Y, Hasegawa Y. Ando Y, et al. Among authors: hasegawa y. Ann Intern Med. 1999 Oct 19;131(8):629-30; author reply 630. doi: 10.7326/0003-4819-131-8-199910190-00018. Ann Intern Med. 1999. PMID: 10523230 No abstract available.

8

Clinical pharmacogenetics of irinotecan (CPT-11).

Ando Y, Hasegawa Y. Ando Y, et al. Among authors: hasegawa y. Drug Metab Rev. 2005;37(3):565-74. doi: 10.1080/03602530500316254. Drug Metab Rev. 2005. PMID: 16257834 Review.

9

Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.

Hasegawa Y, Ando Y, Shimokata K. Hasegawa Y, et al. Expert Rev Mol Diagn. 2006 Jul;6(4):527-33. doi: 10.1586/14737159.6.4.527. Expert Rev Mol Diagn. 2006. PMID: 16824027 Review.

10

Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.

Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y. Shimokata T, et al. Among authors: hasegawa y. Cancer Sci. 2010 Dec;101(12):2601-5. doi: 10.1111/j.1349-7006.2010.01729.x. Epub 2010 Sep 22. Cancer Sci. 2010. PMID: 20860621 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,679 results

Search Page